TOTAL: $262.948M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
AmountRaised(M) |
Investors; Placement Agents; Details (Date) |
Anacor Pharmaceuticals Inc. (Palo Alto, Calif.) |
Loan agreement |
N/A |
$23.4 |
Anacor entered a $30M loan agreement led by Oxford Finance Corp. and partnered with Horizon Technology Finance Corp.; the money will come in three tranches of $10M each and $6.6M will be used to repay debt (3/22) |
Arena Pharmaceuticals Inc. (San Diego) |
Private placement of common stock and preferred stock |
12.15S and 0.01215S of preferred stock |
$17.8 |
Arena raised a total of $35.5M, but $17.7M will be used to prepay a portion of loan principle owed to Deerfield Management; entities affiliated with Deerfield purchased the common and preferred stock (3/30) |
BioCryst Pharmaceuticals Inc. (Research Triangle Park, N.C.) |
Placement of senior secured notes |
N/A |
$30 |
BioCryst raised $30M by monetizing payments from licensee Shionogi & Co. Ltd. for peramivir, a treatment for influenza; BioCryst transferred to JPR Royalty Sub LLC (a new subsidiary) royalty payment rights under its license with Shionogi, and JPR issued $30M in senior secured notes, due 2020 (3/11) |
BioDelivery Sciences International Inc. (Raleigh, N.C.) |
Private placement of common stock |
4.8S |
$15 |
BioDelivery raised $15M in a private placement of 4.8M shares at $3.12 per share; William Blair & Co. LLC is the exclusive placement agent (3/14) |
BioSante Pharmaceuticals Inc. (Lincolnshire, Ill.) |
Registered direct offering |
12.2S and W |
$25.1 |
BioSante raised $25.1M in a registered direct offering; Rodman & Renshaw was the exclusive placement agent for the offering (3/7) |
Biotie Therapies Corp. (Turku, Finland) |
Private placement of common stock |
50S |
€27 |
Biotie raised $37.7M in the private placement (3/15) |
BrainStorm Cell Therapeutics Inc. (New York) |
Private placement of common stock |
12.8S |
$3.6 |
BrainStorm raised $3.6M from the sale of 12.8M shares at 28 cents each, plus warrants that could bring in an additional $8.2M (3/1) |
EpiCept Corp. (Tarrytown, N.Y.) |
Private placement of common stock and warrants |
7.1S and 5.5W |
$4.6 |
EpiCept agreed to sell 7.1M shares of common stock to an institutional investor at 65 cents per share, along with 5.5 year warrants to purchase up to 5.3M more shares at 72 cents (3/30) |
Helix BioPharma Corp. (Aurora, Ontario) |
Private placement of units |
1.6U |
$3.9 |
Helix raised about $3.9M through the sale of 1.6M units at $2.39 each (3/29) |
Immunovaccine Inc. (Halifax, Nova Scotia) |
Investment |
N/A |
$2.9 |
Immunovaccine will receive $2.9M from the Atlantic Canada Opportunities Agency, under the Atlantic Innovation Fund (3/22) |
MethylGene Inc. (Montreal) |
Private placement |
271.3U |
C$34.5 |
MethylGene agreed to privately place about 271.3M units, each consisting of one common share and 0.30 of a common share purchase warrant; investors were Baker Bros. Advisors LLC, Tavistock Life Sciences, OrbiMed Advisors LLC, QVT Financial LP and Tang Capital Partners LP, plus current investors ProQuest Investments III LP and Fonds de solidarite FTQ (3/25) |
NewCo (subsidiary of ProMetic Life Science Inc.; Montreal) |
Investment |
N/A |
$0.75 |
The $750,000 investment is part of a $2.5M commitment (3/1) |
Oncolytics Biotech Inc. (Calgary, Alberta) |
Warrant exercise |
1.2W |
$7.7 |
Oncolytics raised $7.7M in proceeds after its largest institutional shareholder exercised about 1 .2M warrants, issued in connection with a Nov. 8, 2010, financing (3/3) |
Oramed Pharmaceuticals Inc. (Jerusalem) |
Private placement |
10.5S and W for 3.7S |
$3.4 |
Oramed raised $3.4M in a private placement of 10.5M shares and warrants to buy 3.7M shares at 32 cents per unit (3/10) |
PharmaGap Inc. (Ottawa, Ont.) |
Oversubscribed private placement |
N/A |
$0.198 |
PharmaGap raised the initial amount in February; with this oversubscribed amount, the total raised is $1.034M (3/15) |
Prana Biotechnology Ltd. (Melbourne, Australia) |
Private placement of common stock |
27.2S |
A$6.12 |
Prana is raising $6.2M in a private placement of 27.2M shares priced at A$0.225 per share (3/24) |
Rexahn Pharmaceuticals Inc. (Rockville, Md.) |
Registered direct offering |
8.33S and W for 3.33S |
$10 |
Rexahn received commitments from institutional investors to purchase $10M of Rexahn's securities; Rodman & Renshaw acted as exclusive placement agent (3/29) |
SemBioSys Genetics Inc. (Calgary, Alberta) |
Private placement of bonds |
N/A |
$4 |
SemBioSys closed a $4M financing from Concept Capital Management Ltd. in the form of bonds (3/22) |
Tengion Inc. (East Norriton, Pa.) |
Private placement of common stock and warrants |
11.1S and W for 10.5S |
$31.4 |
Tengion raised $31.4M in a PIPE transaction in exchange for issuing about 11.1M shares and warrants to buy about 10.5M to certain investors; Piper Jaffray & Co. served as sole lead placement agent, while Leerink Swann served as co-placement agent (3/2) |
Titan Pharmaceuticals Inc. (South San Francisco) |
Five-year senior secured credit facility |
N/A |
(up to $20M) |
Titan entered a deal with Deerfield Management to provide $20M in credit; some, but not all, proceeds will be used to pay back an Oxford Finance Corp. credit facility (3/17) |
| Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. ** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. | ||||
